Learn more about Genomic Health's diagnostic tests for breast, colon and prostate cancer, which can help patients and their doctor make better, more informed treatment decisions.
DCIS / Stage 0 breast cancer affects 1 out of every 5 women diagnosed with breast cancer in the U.S. Not all DCIS patients will benefit from the addition of radiation therapy to their treatment. Learn more about the Oncotype DX test for DCIS.
Over the past decade, we have redefined personalized medicine through the innovation of Oncotype DX, making genomics an indispensable part of breast, colon and prostate cancer diagnosis and treatment. Learn more about our next decade and how we are continuing to use genomic information to make cancer care smarter.
Global Adoption of Oncotype DX® Breast Cancer Test Continues to Grow with Achievement of Two Significant Intern...
Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX® in Europe
All press releases